Kristin Wynholds - 31 May 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Chief Product Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Issuer symbol
BTTX on OTC
Transactions as of
31 May 2022
Net transactions value
+$12,420
Form type
4
Filing time
02 Dec 2022, 15:15:56 UTC
Previous filing
04 Apr 2022
Next filing
21 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Award $7,728 +5,023 +5.6% $1.54 95,038 31 May 2022 Direct F1
transaction BTTX Common Stock Award $4,692 +3,781 +4% $1.24 98,819 30 Nov 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).